Getein Biotech, Inc (SHA:603387)

Market Cap	4.26B +1.9%
Revenue (ttm)	1.04B -16.5%
Net Income	208.76M -7.7%
EPS	0.41 -8.7%
Shares Out	507.15M
PE Ratio	20.47
Forward PE	n/a
Dividend	0.18 (2.15%)
Ex-Dividend Date	Sep 15, 2025

Volume	8,130,836
Average Volume	6,670,063
Open	8.34
Previous Close	8.38
Day's Range	8.25 - 8.41
52-Week Range	7.31 - 9.23
Beta	0.30
RSI	44.09
Earnings Date	Apr 30, 2026

About Getein Biotech

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, and other fields, such as myocardium, inflammation, renal function, thyroid function, hormones, glucose metabolism, tumor, coagulation, blood...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2002
• Employees: 1,947
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603387

Financial Performance

In 2024, Getein Biotech's revenue was 1.16 billion, a decrease of -14.93% compared to the previous year's 1.37 billion. Earnings were 223.64 million, a decrease of -20.06%.